ArticleThe International journal on drug policy2025
Modeling the impact of changing drug markets and structural determinants on HCV and/or HIV transmission among people who inject drugs in the United States: A rural and urban comparison.
Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe impact of changing drug use patterns on hepatitis C virus (HCV) and HIV incidence among people who inject drugs (PWID) in the US is understudied.
methodsAn HCV and HIV transmission model was calibrated to urban and rural area data (San Diego, CA and Central/Northern Wisconsin). Fentanyl use among PWID was assumed to increase mortality and injecting-related risk of HIV and HCV based on San Diego data. We predicted HCV/HIV incidence with recent trends (in fentanyl use, transition from injecting to smoking drugs, opiate agonist treatment (OAT) and incarceration), and scenarios with no trend changes since 2020. We calculated the population attributable fraction of fentanyl on incidence, comparing to a no fentanyl counterfactual from 2015 to 2025.
resultsHigh and increasing self-reported fentanyl use among PWID was observed in Central/Northern Wisconsin (20 % in 2018 to 45 % in 2021) and San Diego (51 % in 2021 to 66 % in 2023). Between 2015-2025, modeling suggests fentanyl use contributed to 18 % (95 %CI 9-25) and 34 % (95 %CI 26-45) of new HCV infections among PWID in Central/Northern Wisconsin and San Diego, respectively. Fentanyl contributed to 10 % (95 %CI 1-26) of HIV infections in San Diego; no HIV was observed among Central/Northern Wisconsin PWID. Fentanyl-associated risk was mitigated by increased OAT, reduced incarceration (Wisconsin), and shifts from injecting to smoking drugs (San Diego).
conclusionsFentanyl use increased HCV and/or HIV in an urban and rural area, suggesting expanded access to harm reduction, alongside interventions to reduce blood-borne virus transmission risk among PWID who use fentanyl are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.